User:Tanja at Grünenthal/sandbox

In 2018, Grünenthal acquired the pain-related brands Nexium™ and Vimovo™ and the US-rights for Qutenza™ (capsaicin) 8% patch. The company began building a US structure to commercialise the latter asset through Averitas Pharma. Later in 2018, Grünenthal obtained global rights for Qutenza™